MSC for Treatment of Interstitial Lung Disease After Allo-HSCT

Status Recruiting

Clinical Trial Summary

Interstitial lung disease (ILD） is the late pulmonary complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT) leading to high morbidity and mortality. At present, the treatment for ILD after allo-HSCT remains in discussion. In this study, the efficacy of mesenchymal stem cells (MSCs) combined azithromycin as well as glucocorticoid as the treatment of ILD will be evaluated in the recipients of allo-HSCT.

Clinical Trial Description

ILD is a group of diseases involving pulmonary interstitial, alveolar and (or) bronchioles. In the patients receiving allo-HSCT, ILD mainly present as bronchiolitis obliterans syndrome (BOS). ILD after HSCT is characterized by non-responsiveness to treatment, leading to high morbidity and mortality. MSC has been considered as an effective treatment for refractory acute graft-versus-host disease (aGVHD), but the response to treat chronic GVHD (cGVHD), especially refractory BOS, is rarely reported. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02543073
Study type	Interventional
Source	Nanfang Hospital of Southern Medical University
Contact	Ren Lin
Email	lansinglinren@hotmail.com
Status	Recruiting
Phase	Phase 1/Phase 2
Start date	September 2014
Completion date	June 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00766883` - Problem-Solving Education for Caregivers and Patients During Stem Cell Transplant	Phase 2
Recruiting	`NCT06148610` - Evaluation of the Impact of the Use of NewSpringForMe on Transplanted Patients' Quality of Life and Support
Recruiting	`NCT04690933` - AntiCMV molécules Monitoring in Real-life in Stem Cell Recipients
Completed	`NCT02564458` - Fitness in Allogeneic Stem Cell Transplantation	N/A
Not yet recruiting	`NCT01714557` - Prophylactic Piperacillin/Tazobactam in Hematopoietic Stem Cell Transplantation	N/A
Completed	`NCT00701688` - Dose Escalation Study Of Palifermin in Pediatric Research Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation	Phase 1
Completed	`NCT00023530` - Blood and Marrow Transplant Clinical Research Network	N/A
Recruiting	`NCT04092309` - Effect of Angiotensin Converting Enzyme and Sacubitril Valsartan in Patients After Bone Marrow Transplantation	N/A
Completed	`NCT00000603` - Cord Blood Stem Cell Transplantation Study (COBLT)	Phase 2
Completed	`NCT02663622` - Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002)	Phase 2
Recruiting	`NCT04937634` - Pharmacokinetic Study of Melphalan in Pediatric Hematopoietic Stem Cell Transplantation	Phase 1
Recruiting	`NCT04203108` - ATG in HLA-matched Sibling HSCT as GVHD Prophylaxis	Phase 4
Withdrawn	`NCT03279133` - Ledipasvir/Sofosbuvir Treatment for Hepatitis C in HCT Recipients.	Phase 4
Completed	`NCT03654599` - Effects of Digital Stories Intervention on Psychosocial Well-being	N/A
Completed	`NCT05151406` - Myths and Misconceptions About HSCT in a Limited Resource Region	N/A
Completed	`NCT02241005` - Theraworx Bath Wipes Versus Standard Bath Wipes in the Reduction of Vancomycin-Resistant Enterococci	N/A
Recruiting	`NCT03689465` - PTCy-ATG vs ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis	Phase 4
Recruiting	`NCT04868786` - Pharmacokinetics and Pharmacodynamics of Mycophenolate Mofetil in Pediatric Hematopoietic Stem Cell Transplantation	Phase 1
Recruiting	`NCT03010579` - Erythropoietin in the Treatment of Anemia After Autologous Hematopoietic Stem Cell Transplantation	Phase 4
Active, not recruiting	`NCT00959140` - Standardization of CD3+ T Cell Dose for Patients Receiving Allogeneic Peripheral Blood Stem Cell Transplantation From Matched Related Donors	N/A